Oesophageal Cancer Management
On this page
Direct answer
Oesophageal cancer is two diseases under one name: squamous cell carcinoma of the mid and upper oesophagus, linked to tobacco, alcohol, very hot beverages and areca nut, and adenocarcinoma of the distal oesophagus and gastro-oesophageal junction arising in Barrett's metaplasia. Resectable locally advanced disease of either histology takes neoadjuvant chemoradiation — the CROSS regimen of weekly carboplatin (AUC 2) and paclitaxel (50 mg/m²) with 41.4 Gy in 23 fractions — then oesophagectomy, with perioperative FLOT an alternative for adenocarcinoma. The cervical oesophagus is managed like a head-and-neck cancer with definitive chemoradiation rather than surgery. Metastatic adenocarcinoma requires HER2 and PD-L1 testing for trastuzumab and checkpoint-inhibitor combinations, while metastatic squamous disease is treated with immunotherapy plus platinum-fluoropyrimidine chemotherapy.
What you must remember
- Histology decides the geography: adenocarcinoma sits in the lower third and junction (Barrett's, obesity, reflux); squamous carcinoma dominates the middle and upper third — and in India's north-eastern and Gangetic "oesophageal cancer belt" squamous disease dominates, with hot beverage intake classified by IARC as probably carcinogenic (Group 2A).
- Staging trio: endoscopic ultrasound for depth and coeliac nodes, PET-CT for distant disease, and laparoscopy for junctional tumours to exclude peritoneal spread.
- CROSS regimen: weekly carboplatin AUC 2 plus paclitaxel 50 mg/m² for five weeks with 41.4 Gy in 23 fractions, surgery four to six weeks later — improved resectability and survival in both histologies, squamous more than adenocarcinoma.
- FLOT alternative for adenocarcinoma: perioperative docetaxel, oxaliplatin, leucovorin and 5-fluorouracil, each cycle two weeks, three before and three after surgery — it outperformed the older MAGIC epirubicin-cisplatin-capecitabine regimen.
- Cervical oesophagus: definitive chemoradiation to 50.4–61 Gy with cisplatin-fluorouracil, reserving salvage surgery for persistence — operating here sacrifices the larynx.
- Adjuvant nivolumab (CheckMate-577): for residual pathologic disease after neoadjuvant chemoradiation and resection, roughly doubling disease-free survival — immunotherapy's entry into curative-intent care.
- Metastatic first-line: trastuzumab with cisplatin plus capecitabine or 5-FU for HER2-positive adenocarcinoma (ToGA heritage); nivolumab plus FOLFOX or XELOX per CheckMate-649, or pembrolizumab plus cisplatin-5-FU per KEYNOTE-590, both richest in PD-L1 CPS ≥ 5; MSI-high tumours take pembrolizumab alone.
- Second line: paclitaxel with ramucirumab (RAINBOW); taxane or irinotecan otherwise.
- Never neglect nutrition: feeding jejunostomy or nasojejunal support through chemoradiation, self-expanding metal stents for malignant fistula or palliation of dysphagia, and vigilance for anastomotic leak after Ivor-Lewis two-field oesophagectomy.
Planning a junctional adenocarcinoma from diagnosis to theatre
A 57-year-old banker reports four months of progressive dysphagia and 8 kg weight loss; endoscopy shows an ulcerated Siewert II junctional tumour — adenocarcinoma, HER2 positive. EUS stages it T3 with one coeliac node; PET-CT and laparoscopy exclude distant and peritoneal disease. The board chooses perioperative FLOT with an early feeding jejunostomy to protect nutrition; after three cycles he proceeds to Ivor-Lewis oesophagectomy. Residual disease on pathology brings adjuvant nivolumab for a year per CheckMate-577, and his HER2 positivity is banked should metastatic disease appear. Had this been a mid-oesophageal squamous carcinoma in a 64-year-old areca-nut user from Assam, CROSS chemoradiation still applies, definitive chemoradiation alone is a legitimate alternative, and HER2 testing is irrelevant — the branch points are histology, location and resectability, settled before any drug is written.
Where students slip
Four slips dominate. Candidates recommend oesophagectomy for cervical-oesophageal squamous cancer, forgetting definitive chemoradiation preserves the larynx and is the standard. EUS is ordered after a stent is placed, when the stent makes depth assessment unreliable — staging must precede palliation whenever cure is on the table. HER2 testing is requested for squamous carcinoma, where it has no first-line role, while being omitted in junctional adenocarcinoma where trastuzumab changes outcome. And nutrition is an afterthought despite weight loss being the strongest predictor of chemoradiation intolerance — a jejunostomy sited at staging laparoscopy is a decision the exam expects, as is the warning that a stent across a junctional tumour bound for surgery complicates the anastomosis.
Frequently asked questions
What are the drugs and doses in the CROSS regimen?
Weekly carboplatin AUC 2 and paclitaxel 50 mg/m² for five weeks with concurrent 41.4 Gy in 23 fractions, followed by oesophagectomy four to six weeks later.
How does perioperative FLOT differ from CROSS?
FLOT is chemotherapy without radiotherapy — docetaxel, oxaliplatin, leucovorin and 5-fluorouracil given three cycles before and three after surgery — the perioperative standard preferred for junctional adenocarcinoma.
How is cancer of the cervical oesophagus treated?
Definitive concurrent chemoradiation to 50.4–61 Gy with cisplatin-based chemotherapy, managed like other head-and-neck squamous cancers; surgery is reserved for residual or recurrent disease because it sacrifices the larynx.
What is first-line therapy for HER2-positive metastatic junctional adenocarcinoma?
Trastuzumab combined with cisplatin and a fluoropyrimidine; testing tumours for HER2 by immunohistochemistry and FISH before cycle one is mandatory for adenocarcinoma histology.
Which patients benefit from adjuvant nivolumab after oesophagectomy?
Those with residual pathologic disease (non-complete response) after neoadjuvant chemoradiation, per CheckMate-577, which roughly doubled disease-free survival across both histologies.
When is a self-expanding metal stent the right choice?
For malignant dysphagia in palliative settings or tracheo-oesophageal fistula — not as a bridge to surgery, where it interferes with the anastomosis.